COMPLEMENTARY LYMPHADENECTOMY IN MELANOMA: A REVIEW OF THE MSLTII STUDY
DOI:
https://doi.org/10.51891/rease.v12i11.32402Keywords:
Melanoma, Sentinel Lymph Node, Lymph Node Dissection, MSLTII Trial, Public HealthAbstract
Cutaneous melanoma accounts for the highest mortality among skin cancers, demanding accurate staging and precise surgical management. Historically, sentinel lymph node biopsy (SLNB) positivity mandated immediate completion lymph node dissection. However, the Multicenter Selective Lymphadenectomy Trial II (MSLTII) shifted this paradigm by demonstrating overall survival equivalence between immediate completion dissection and active nodal observation using Doppler ultrasonography. This article reviews the MSLTII trial findings and evaluates its clinical applicability within the Brazilian Public Health System (SUS). Based on literature review and guidelines from the Brazilian Melanoma Group, we highlight that the lack of public coverage for adjuvant immunotherapy (e.g., ipilimumab) and targeted therapies restricts the direct application of MSLTII protocols in Brazil. Consequently, management of SLN-positive patients in SUS requires individualized decision-making, supported by predictive nomograms (such as Bertolli et al.) to stratify non-sentinel node involvement risk and guide surgical intervention.
Downloads
Downloads
Published
Issue
Section
Categories
License
Atribuição CC BY